Platelet abnormalities in adults with severe pulmonary arterial hypertension related to congenital heart defects (Eisenmenger syndrome)

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
Anna RemkováMonika Kaldarárová

Abstract

Patients with severe pulmonary arterial hypertension suffer from life-threatening thrombotic and bleeding complications. The aim of this study was to compare selected platelet, endothelial, and coagulation parameters in healthy volunteers and patients with severe pulmonary arterial hypertension because of congenital heart defects. The study included healthy volunteers (n = 50) and patients with cyanotic congenital heart defects classified as Eisenmenger syndrome (n = 41). We investigated platelet count, mean platelet volume, and platelet aggregation - spontaneous and induced by various concentrations of five agonists. Von Willebrand factor (vWF), fibrinogen, factor VIII and XII, plasminogen activator inhibitor, antithrombin, D-dimer, and antiphospholipid antibodies were also investigated. We found a decreased platelet count [190 (147-225) vs. 248 (205-295) 10 l, P < 0.0001], higher mean platelet volume [10.9 (10.1-12.0) vs. 10.2 (9.4-10.4) fl, P < 0.0001], and significantly decreased platelet aggregation (induced by five agonists, in various concentrations) in patients with Eisenmenger syndrome compared with controls. These changes were accompanied by an increase of plasma vWF antigen [141.6 (108.9-179.1) vs. 117.4 (9.2-140.7) ...Continue Reading

References

Apr 4, 2000·European Journal of Internal Medicine·A RemkováH Kratochvíl'ová
Feb 28, 2007·Circulation·Gerhard-Paul Diller, Michael A Gatzoulis
Aug 2, 2007·Hematology/oncology Clinics of North America·Paul F Bray
Aug 19, 2007·Journal of the American College of Cardiology·Craig S BrobergMichael A Gatzoulis
Feb 28, 2009·Journal of the American College of Cardiology·Maurice Beghetti, Nazzareno Galiè
Aug 3, 2010·Thrombosis Research·Mehmet Mustafa CanVictor Serebruany
Aug 31, 2010·European Heart Journal·Helmut BaumgartnerUNKNOWN ESC Committee for Practice Guidelines (CPG)
Mar 17, 2011·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Ercan VarolMehmet Ozaydin
Jan 10, 2012·International Journal of Cardiology·H Ardeschir GhofraniHorst Olschewski
Mar 1, 2012·Congenital Heart Disease·Julio SandovalCraig S Broberg
Oct 31, 2013·European Heart Journal·Konstantinos DimopoulosMichael A Gatzoulis
Jun 24, 2014·Platelets·Efrén Martínez-Quintana, Fayna Rodríguez-González

❮ Previous
Next ❯

Software Mentioned

GraphPad Prism
GraphPad

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Blood Coagulation Signaling Pathways

Coagulation is the process by which a blood clot is formed. This process includes both the formation of a platelet plug as well as a cascade of clotting factors resulting in the formation of fibrin strands. Find the latest research on coagulation signaling pathways here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

© 2021 Meta ULC. All rights reserved